Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
Authors:
Open Access
- 25 March 2022
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (8) , 1999-2012.e6
Abstract
No abstract availableKeywords
Funding Information
- Celgene
- Allergopharma
- Austrian Science Fund (F4704)
- Austrian Science Fund (P32470-B)
- Austrian Science Fund (F4701-B20)
- Austrian Science Fund (F4704-B20)
- Incyte
- Division of Intramural Research
- National Institute of Allergy and Infectious Diseases
- Novartis
- Teva Pharmaceutical Industries
- AbbVie
- National Institutes of Health
This publication has 108 references indexed in Scilit:
- Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical ConsiderationsThe Journal of Allergy and Clinical Immunology: In Practice, 2013
- IgE and mast cells in allergic diseaseNature Medicine, 2012
- Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus ProposalInternational Archives of Allergy and Immunology, 2011
- Survey of aspirin administration in systemic mastocytosisProstaglandins & Other Lipid Mediators, 2009
- Mast cells and mastocytosisBlood, 2008
- Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosisClinical Rheumatology, 2006
- IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosisClinical Immunology, 2005
- Leukotriene-Receptor Inhibition for the Treatment of Systemic MastocytosisNew England Journal of Medicine, 2004
- The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosisRheumatology, 1997
- SEVERE OSTEOPOROSIS DUE TO SYSTEMIC MAST CELL DISEASE: SUCCESSFUL TREATMENT WITH INTERFERON ALPHA-2BRheumatology, 1996